title: Strategies to reduce hepatitis C virus recurrence after liver transplantation.
abstract: Hepatitis C virus (HCV) is a major health problem that leads to chronic hepatitis, cirrhosis and hepatocellular carcinoma, being the most frequent indication for liver transplantation in several countries. Unfortunately, HCV re-infects the liver graft almost invariably following reperfusion, with an accelerated history of recurrence, leading to 10%-30% of patients progressing to cirrhosis within 5 years of transplantation. In this sense, some groups have even advocated for not re-transplanting this patients, as lower patient and graft outcomes have been reported. However, the management of HCV recurrence is being optimized and several strategies to reduce post-transplant recurrence could improve outcomes, decrease the rate of re-transplantation and optimize the use of available grafts. Three moments may be the focus of potential actions in order to decrease the impact of viral recurrence: the pre-transplant moment, the transplant environment and the post-transplant management. In the pre-transplant setting, it is not well established if reducing the pre transplant viral load affects the risk for HCV progression after transplant. Obviously, antiviral treatment can render the patient HCV RNA negative post transplant but the long-term benefit has not yet been fully established to justify the cost and clinical risk. In the transplant moment, factors as donor age, cold ischemia time, graft steatosis and ischemia/reperfusion injury may lead to a higher and more aggressive viral recurrence. After the transplant, discussion about immunosuppression and the moment to start the treatment (prophylactic, pre-emptive or once-confirmed) together with new antiviral drugs are of interest. This review aims to help clinicians have a global overview of post-transplant HCV recurrence and strategies to reduce its impact on our patients.
authors.affiliation: Ruben Ciria, Shirin Elizabeth Khorsandi, Diego Davila, Abid Suddle, Hector Vilca-Melendez, Nigel Heaton, Institute of Liver Studies, King's College Hospital, London SE5 9RS, United Kingdom.
authors.forename: Ruben
authors.initials: R
authors.lastname: Ciria
authors.forename: María
authors.initials: M
authors.lastname: Pleguezuelo
authors.forename: Shirin Elizabeth
authors.initials: SE
authors.lastname: Khorsandi
authors.forename: Diego
authors.initials: D
authors.lastname: Davila
authors.forename: Abid
authors.initials: A
authors.lastname: Suddle
authors.forename: Hector
authors.initials: H
authors.lastname: Vilca-Melendez
authors.forename: Sebastian
authors.initials: S
authors.lastname: Rufian
authors.forename: Manuel
authors.initials: M
authors.lastname: de la Mata
authors.forename: Javier
authors.initials: J
authors.lastname: Briceño
authors.forename: Pedro López
authors.initials: PL
authors.lastname: Cillero
authors.forename: Nigel
authors.initials: N
authors.lastname: Heaton
keywords: Hepatitis C virus; Liver; Outcomes; Recurrence; Transplantation